Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Inflammation: The Missing Link

June 6, 2014
By Noam A. VanderWalde, MD
Article
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

At the ASCO/AACR Joint Session on Inflammatory Cells and Cancer, Dr. Andrew Dannenberg from Weill Cornell Medical College, gave a fascinating lecture titled “Stromal Inflammation and Solid Tumors.”

Noam VanderWalde, MD

On Saturday, the second day of the ASCO Annual Meeting, I went to the ASCO/AACR Joint Session on Inflammatory Cells and Cancer. At this session, Andrew Dannenberg, MD, of Weill Cornell Medical College, gave a fascinating lecture titled “Stromal Inflammation and Solid Tumors.”

Oncologists have long known that there is an association between certain lifestyles (ie, smoking, obesity, sedentary) and the likelihood of developing cancer, response to treatment of cancer, and survival after cancer. However, prior to this talk, I had never heard a potential mechanism for this association so elegantly explained.

Dr. Dannenberg’s underlying hypothesis is based on the data showing that chronic inflammation leads to increased rates of cancer. This certainly fits with the data showing increased rates of certain cancers in patients who have chronic inflammatory disease (ie, Crohn’s disease, ulcerative colitis, etc.). With that assumption, Dr. Dannenberg and his team sought to identify a connection between obesity and chronic inflammation in the breast. They started with mouse models and eventually moved on to human studies, which found that an increase in what they described as “crown-like structures of inflammatory cells” surrounding white adipose tissue correlated very strongly with increases in pro-inflammatory cytokines, including IL-6, IL-1B, and TNF-a. These pro-inflammatory cytokines also correlated strongly with an increase in aromatase. This is particularly interesting given the results of the IBCSG TEXT and SOFT trials presented at the ASCO plenary session, which showed a disease-free survival benefit with the use of an aromatase inhibitor over tamoxifen in premenopausal women who received ovarian suppression (known to cause weight gain).

One additional interesting fact demonstrated by the data is that although there was a strong correlation between these crown-like structures in the breast and obesity (with as many as 90% of obese women having them), there was still a large number of non-obese patients who had these structures (35% of the BMI < 25 group; 54% of the overweight (non-obese) group). Why some non-obese women have these structures that are associated with inflammation is unclear. Could it be due to sedentary lifestyle, age, or diet? Neil Iyengar, MD, the first author of the poster presentation of this data, admitted that all of these were potential explanations and that they are currently being looked into. He also explained that they are looking into possible systemic/blood markers that may be better predictors of inflammation than obesity.

The elegant experiments and studies performed by Dr. Dannenberg and his team are fascinating and are certainly a step forward in explaining the link between lifestyle and cancer. How this may impact our patients in the future is still to be determined. One personal concern is that many women who live healthy lifestyles may think that it is impossible for them to get cancer. Certainly, I have met many newly diagnosed breast cancer patients who eat healthy, exercise, and have no family history of cancer, and thus wonder how cancer happened to them. It is possible that systemic markers of inflammation may lead to different screening recommendations for those at “higher risk” for developing cancer, or may even become earlier screening methods themselves.

The current data should not make “healthier” women feel they are immune to developing cancer. I hope that women who eat healthy and exercise continue with recommended screening. Despite this minor concern, I am hopeful that as we learn more about the connection between lifestyle, inflammation, and cancer, we can better prevent and treat all cancers.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Related Content
Advertisement

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC

Kristi Rosa
December 24th 2025
Article

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.

FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT

Tim Cortese
December 22nd 2025
Article

Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Gedatolisib Combo With/Without Palbociclib May Be New SOC in PIK3CA Wild-Type Breast Cancer

Gedatolisib Combo With/Without Palbociclib May Be New SOC in PIK3CA Wild-Type Breast Cancer

Kristi Rosa
December 21st 2025
Article

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.


Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Pyrotinib Combo Sustains Survival Benefits in HER2+ Breast Cancer Trial

Russ Conroy
December 21st 2025
Article

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Related Content
Advertisement

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC

Kristi Rosa
December 24th 2025
Article

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.

FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT

Tim Cortese
December 22nd 2025
Article

Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Gedatolisib Combo With/Without Palbociclib May Be New SOC in PIK3CA Wild-Type Breast Cancer

Gedatolisib Combo With/Without Palbociclib May Be New SOC in PIK3CA Wild-Type Breast Cancer

Kristi Rosa
December 21st 2025
Article

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.


Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Pyrotinib Combo Sustains Survival Benefits in HER2+ Breast Cancer Trial

Russ Conroy
December 21st 2025
Article

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.